CTLA4 and neoplasm: For B7-H3, its immunomodulatory role suggests potential synergy with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA4 therapies, to overcome immune resistance and enhance anti-tumor immunity [39].